11 November 2026 – Sapio Group, through its UK subsidiary Baywater Healthcare UK Limited (“Baywater”), has completed the acquisition of Medical Gas Solutions Ltd (“MGS”), a UK-based company specialising in the supply of a medicinal gas mixture of nitrous oxide and oxygen to the National Health Service (NHS) – for applications outside home care – and to private customers. MGS is also an existing supplier to Baywater, providing oxygen cylinder filling services.
The transaction supports the Group’s long-term strategy in the cylinder filling sector, strengthening its operational capabilities and enhancing the reliability of supply. The acquisition is also aligned with the strategic priorities of the RISE strategic plan, which aims to contribute to the development of national healthcare systems by providing increasingly reliable, high-quality solutions.
MGS will continue to operate and serve its customers as a separate entity, maintaining its existing operational sites. Accordingly, completion of the acquisition will not result in any changes to day-to-day commercial contacts or current operational arrangements.
“The acquisition of MGS is consistent with our growth plans and Sapio’s ambition to strengthen its position as a leading player in the European healthcare sector,” said Mario Paterlini, CEO of Sapio Group. “We firmly believe that sustainable growth is driven by targeted investments that expand our expertise, strengthen operational resilience and support the long-term development of national healthcare systems. With MGS, we are consolidating Baywater’s platform in the UK and laying the foundations for continued growth in the country.”
Adam Sullivan, CEO of Baywater Healthcare, commented: “At Baywater, our goal has always been to ensure that patients and customers receive safe, reliable and uninterrupted care and services. Bringing MGS into the Group strengthens our ability to deliver on this commitment, while creating new opportunities for growth and innovation. We are delighted to welcome the MGS team and look forward to building a successful future together.”
About Sapio Group
Founded in 1922 in Monza, Italy, Sapio Group is an Italian multinational company owned 51% by the Dossi and Colombo families and 49% by Air Products and Chemicals (USA).
The Group operates in the industrial gases, medical gases and home healthcare sectors across Italy, France, the United Kingdom, Germany, Slovenia, Turkey, Spain and Portugal, employing more than 3,500 people and generating annual revenue of approximately €1 billion.
In addition to supplying medical gases to hospitals and healthcare facilities, Sapio provides medical devices for oxygen therapy, mechanical ventilation, artificial nutrition, remote patient monitoring, sleep medicine, assisted home haemodialysis, specialist pharmaceuticals, integrated home healthcare services and cryotherapy solutions.
In the homecare sector, the Group also develops innovative solutions designed to improve patients’ quality of life and support greater adherence to prescribed therapies, providing care to more than 400,000 patients across Europe each year.
About Baywater Healthcare
Baywater Healthcare, part of Sapio Group, is one of the UK’s leading providers of home respiratory care and the country’s largest supplier of home oxygen therapy services to the National Health Service (NHS).
Working in partnership with the NHS, Baywater provides an expanding range of specialist services focused on respiratory conditions and chronic disease management, with the aim of improving clinical outcomes and helping patients achieve greater independence.